LEXICON PHARMACEUTICALS, INC. Operating Lease, Liability, Noncurrent
LEXICON PHARMACEUTICALS, INC. (LXRX) had Operating Lease, Liability, Noncurrent of $6.16 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability, Noncurrent $6.16M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $6.38M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $6.60M; Operating Lease, Liability, Noncurrent as first filed $6.59M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $6.79M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $6.16M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.38M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $6.60M 10-Q · filed 2026-08-06 | $6.59M 10-K · filed 2026-03-05 |
| 2025-09-30 | $6.79M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $4.43M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $4.52M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $4.60M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $4.68M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $4.89M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $5.08M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $5.30M 10-K · filed 2025-03-07 | $5.26M 10-K · filed 2024-03-25 |
| 2023-09-30 | $5.44M 10-Q · filed 2023-11-08 | |
| 2022-12-31 | $5.42M 10-K · filed 2024-03-25 | |
| 2019-09-30 | $1.22M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.32M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $1.43M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |